Continuous human metastin 45-54 infusion desensitizes G protein-coupled receptor 54-induced gonadotropin-releasing hormone release monitored indirectly in the juvenile male Rhesus monkey (Macaca mulatta): a finding with therapeutic implications.
The effect of continuous administration of the C-terminal fragment of metastin, the ligand for the G protein-coupled receptor, GPR54, on GnRH-induced LH secretion was examined in three agonadal, juvenile male monkeys whose responsiveness to GnRH was heightened by pretreatment with a chronic pulsatile iv infusion of synthetic GnRH. After bolus injection of 10 microg human (hu) metastin 45-54 (equivalent to kisspeptin 112-121), the GPR54 agonist was infused continuously at a dose of 100 microg/h and elicited a brisk LH response for approximately 3 h. This rise was then followed by a precipitous drop in LH despite continuous exposure of GPR54 to metastin 45-54. On d 4, during the final 3 h of the infusion, single boluses of hu metastin 45-54 (10 microg), N-methyl-DL-aspartic acid (NMDA) (10 mg/kg) and GnRH (0.3 microg) were administered to interrogate each element of the metastin-GPR54-GnRH-GnRH receptor cascade. Although the NMDA and GnRH boluses were able to elicit LH pulses, that of hu metastin 45-54 was not, demonstrating functional integrity of GnRH neurons (NMDA) and GnRH receptors (NMDA and GnRH) but desensitization of GPR54. The desensitization of GPR54 by continuous hu metastin 45-54 administration has therapeutic implications for a variety of conditions currently being treated by GnRH and its analogs, including restoration of fertility in patients with abnormal GnRH secretion (i.e. idiopathic hypogonadotropic hypogonadism and hypothalamic amenorrhea) and selective, reversible suppression of the pituitary-gonadal axis to achieve suppression of gonadal steroids (i.e. precocious puberty, endometriosis, uterine fibroids, and prostate cancer).
Seminara
Stephanie B
SB
Reproductive Endocrinology Unit, Massachusetts General Hospital, Boston, 02114, USA.
Dipietro
Meloni J
MJ
Ramaswamy
Suresh
S
Crowley
William F
WF
Plant
Tony M
TM
D000818:Animals; D001681:Biological Assay; D001835:Body Weight; D006801:Humans; D007262:Infusions, Intravenous; D059648:Kisspeptins; D008024:Ligands; D007986:Luteinizing Hormone / Q000378:metabolism; D008253:Macaca mulatta; D008297:Male; D008954:Models, Biological; D016202:N-Methylaspartate / Q000737:chemistry; D010902:Pituitary Gland / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism; D011506:Proteins / Q000008:administration & dosage* / Q000737:chemistry; D043562:Receptors, G-Protein-Coupled; D044088:Receptors, Galanin / Q000378:metabolism*; D000074502:Receptors, Kisspeptin-1; D011966:Receptors, LHRH / Q000378:metabolism; D013997:Time Factors; D025521:Tumor Suppressor Proteins
C106628:KISS1 protein, human; C118688:KISS1R protein, human; D059648:Kisspeptins; D008024:Ligands; D011506:Proteins; D043562:Receptors, G-Protein-Coupled; D044088:Receptors, Galanin; D000074502:Receptors, Kisspeptin-1; D011966:Receptors, LHRH; D025521:Tumor Suppressor Proteins; D016202:N-Methylaspartate; D007986:Luteinizing Hormone